Results 231 to 240 of about 5,542 (243)

Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study

Annals of the Rheumatic Diseases, 2018
Josef S Smolen, Jung-Yoon Choe, Roman Yatsyshyn   +2 more
exaly  

Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial

The Lancet Gastroenterology and Hepatology, 2018
Igor N Bondarenko, Vikas Ostwal Dm, Ana Del Campo García   +2 more
exaly  

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab

Arthritis and Rheumatology, 2018
Frank H J Van Den Hoogen, Alfons A Den Broeder   +1 more
exaly  

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis

Arthritis and Rheumatology, 2018
Michael E Weinblatt
exaly  

Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars

Nature Reviews Drug Discovery, 2012
John R Engen
exaly  

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!

BioDrugs, 2019
Isabelle Huys, Arnold G Vulto, Steven R A Simoens   +2 more
exaly  

Analytical characterization of biosimilar antibodies and Fc-fusion proteins

TrAC - Trends in Analytical Chemistry, 2013
Alain Beck, Daniel Ayoub, Christine Carapito   +2 more
exaly  

The Japan PDMA will require pharmaceutical companies to include risk management plans in all applications, for new drug or biosimilar products,

Reactions Weekly, 2012
openaire   +2 more sources

EE339 The Biosimilars’ Economic Evaluation in Contrast With Judicializations’ Economic Impacts of the Pharmaceutical Assistance in Brazil

Value in Health
E Tanaka, GK Tanaka, L. Assunção-Costa, E Blay   +3 more
openaire   +1 more source

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial

Journal of Internal Medicine, 2019
exaly